Cartridge and method for increasing myocardial function

Abstract

The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions that affect myocardial function and to related methods. The cartridge can be used in treating a subject with myocardial dysfunction, such as a subject with chronic heart failure and/or acute decompensated heart failure.

What is claimed is: 
     
         1 . A method of increasing myocardial function in a subject with chronic heart failure, the method comprising:
 (a) extracorporeally sequestering activated leukocytes and/or activated platelets present in a body fluid of the subject in a cartridge comprising
 (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port, and 
 (ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering activated leukocytes and/or activated platelets, if present in a body fluid entering the housing via the fluid inlet port, and the body fluid is introduced into the housing via the fluid inlet port under conditions that permit sequestration of the activated leukocytes and/or activated platelets on the fluid contacting surface of the solid support; and 
   (b) treating the sequestered leukocytes and/or platelets to inhibit release of a pro-inflammatory substance or to deactivate the leukocytes and/or platelets thereby to increase myocardial function of the subject when compared to the myocardial function of the subject prior to treatment, wherein the myocardial function is selected from the group consisting of left ventricular ejection fraction, cardiac output, systemic vascular resistance, left ventricular stroke volume, aortic pressure, left ventricular pressure, peak rate of change of left ventricular pressure during isovolumic contraction and relaxation, left ventricular end-diastolic pressure, myocardial oxygen consumption, and coronary flow reserve.   
     
     
         2 . The method of  claim 1 , wherein the SA/IV ratio of the cartridge provided in step (a) is greater than 25 cm −1 . 
     
     
         3 . The method of  claim 1 , wherein the SA/IV ratio of the cartridge provided in step (a) is in the range of 25 cm −1  to 2,000 cm −1 . 
     
     
         4 . The method of  claim 1 , wherein the SA/IV ratio of the cartridge provided in step (a) is no greater than 80 cm −1 . 
     
     
         5 . The method of  claim 1 , wherein the solid support is disposed within the housing at a packing density in the range from 20% to 65%. 
     
     
         6 - 7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein the solid support comprises a fiber. 
     
     
         9 . (canceled) 
     
     
         10 . The method of  claim 1 , wherein the SA of the cartridge provided in step (a) is in the range of from 0.1 m 2  to 5.0 m 2 . 
     
     
         11 - 14 . (canceled) 
     
     
         15 . The method of  claim 1 , wherein the inner volume is in the range of from 15 cm 3  to 120 cm 3 . 
     
     
         16 . The method of  claim 1 , further comprising permitting the body fluid to exit the cartridge via the fluid outlet port at a flow rate in the range of 10 cm 3 /minute to 8,000 cm 3 /minute. 
     
     
         17 . The method of  claim 1 , wherein the solid support is substantially parallel to the direction of fluid flow within the cartridge. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 1 , wherein, in step (b), the leukocytes and/or platelets are treated with a calcium chelating agent. 
     
     
         20 . The method of  claim 19 , wherein the calcium chelating agent is citrate. 
     
     
         21 - 23 . (canceled) 
     
     
         24 . The method of  claim 1 , wherein the subject has myocardial dysfunction secondary to inflammatory cell penetration of heart tissue. 
     
     
         25 . The method of  claim 1 , wherein the subject has received a heart transplant. 
     
     
         26 . The method of  claim 1 , wherein the body fluid is blood. 
     
     
         27 . The method of  claim 1 , wherein the increased myocardial function is maintained for at least 6 hours after termination of the treatment in step (b). 
     
     
         28 . The method of  claim 27 , wherein the increased myocardial function is maintained for at least 24 hours after termination of the treatment in step (b). 
     
     
         29 . A method of increasing myocardial function in a subject with chronic heart failure, the method comprising:
 (a) extracorporeally sequestering activated leukocytes and/or activated platelets present in a body fluid of the subject; and   (b) treating the sequestered leukocytes and/or platelets to inhibit release of a pro-inflammatory substance or to deactivate the leukocytes and/or platelets thereby to increase myocardial function of the subject when compared to the myocardial function of the subject prior to treatment, wherein the myocardial function is selected from the group consisting of left ventricular ejection fraction, cardiac output, systemic vascular resistance, left ventricular stroke volume, aortic pressure, left ventricular pressure, peak rate of change of left ventricular pressure during isovolumic contraction and relaxation, left ventricular end-diastolic pressure, myocardial oxygen consumption, and coronary flow reserve.   
     
     
         30 . A method of increasing myocardial function in a subject with acute decompensated heart failure (ADHF), the method comprising:
 (a) extracorporeally sequestering activated leukocytes and/or activated platelets present in a body fluid of the subject; and   (b) treating the sequestered leukocytes and/or platelets to inhibit release of a pro-inflammatory substance or to deactivate the leukocytes and/or platelets thereby to increase myocardial function of the subject when compared to the myocardial function of the subject prior to treatment.   
     
     
         31 - 62 . (canceled) 
     
     
         63 . A method of treating a subject having or at risk of developing an inflammatory condition associated with acute decompensated heart failure (ADHF), the method comprising:
 (a) providing a cartridge comprising
 (i) a rigid housing defining an inner volume (IV), a fluid inlet port and a fluid outlet port, wherein the inner volume is in fluid flow communication with the fluid inlet port and the fluid outlet port; and 
 (ii) a solid support disposed within the housing and defining a fluid contacting surface with a surface area (SA) capable of sequestering an activated leukocyte, if present in a body fluid entering the housing via the fluid inlet port; and 
   (b) introducing a body fluid from a subject into the housing via the fluid inlet port under conditions that permit sequestration of an activated leukocyte and/or an activated platelet on the fluid contacting surface of the solid support.   
     
     
         64 - 100 . (canceled)